Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
MIAMI, Feb. 27, 2017 -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the fourth quarter ended December 31, 2016 after the close of the U.S. financial markets on Wednesday, March 1, 2017.
OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Wednesday, March 1, 2017.
Conference Call & Webcast Information
WHEN: Wednesday, March 1, 2017, 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 80392791
WEBCAST: http://investor.opko.com/events.cfm
For those unable to participate in the live conference call or webcast, a replay will be available beginning March 1, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 80392791. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.
Contacts: OPKO Health, Inc. David Malina, 305-575-4137 [email protected] Investor Relations Or Bio-Reference Tara MacCay, 305-5754195 [email protected] Media Rooney & Associates Terry Rooney, 212-223-0689 [email protected] Or Marion Janic, 212-223-4017 [email protected] Investors LHA Anne Marie Fields, 212-838-3777 [email protected] Or Bruce Voss, 310-691-7100 [email protected]
